Home LiteratureArticle Details
PMID: 21072891 Published · ppublish English Journal Article Review

Histopathology of nonalcoholic fatty liver disease.

World journal of gastroenterology ·Vol. 16 ·No. 42 ·2010-11-14 ·Pages 5286-96

Brunt EM, Tiniakos DG

Abstract

Histological analysis of liver biopsies remains a standard against which other methods of assessment for the presence and amount of hepatic injury due to nonalcoholic fatty liver disease (NAFLD) are measured. Histological evaluation remains the sole method of distinguishing steatosis from advanced forms of NAFLD, i.e. nonalcoholic steatohepatitis (NASH) and fibrosis. Included in the lesions of NAFLD are steatosis, lobular and portal inflammation, hepatocyte injury in the forms of ballooning and apoptosis, and fibrosis. However, patterns of these lesions are as distinguishing as the lesions themselves. Liver injury in adults and children due to NAFLD may have different histological patterns. In this review, the rationale for liver biopsy, as well as the histopathological lesions, the microscopically observable patterns of injury, and the differential diagnoses of NAFLD and NASH are discussed.

MeSH Terms
Adult Biopsy Fatty Liver/diagnosis,pathology,physiopathology Fibrosis Humans Liver/pathology,surgery Liver Transplantation Non-alcoholic Fatty Liver Disease Severity of Illness Index
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Brunt Elizabeth M
Department of Pathology and Immunology, Washington University School of Medicine, 660 S. Euclid Ave., Campus Box 8118, St. Louis, MO 63110, United States. [email protected]
Tiniakos Dina G
References (143)
143 references, click to expand
  1. Mallory body--a disease-associated type of sequestosome.
    Hepatology. 2002 May;35(5):1053-62 PMID: 11981755
  2. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study.
    Hepatology. 2009 Oct;50(4):1113-20 PMID: 19637190
  3. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
    Gastroenterology. 2008 Jul;135(1):100-10 PMID: 18503774
  4. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.
    Lancet. 2004 Jan 10;363(9403):157-63 PMID: 14726171
  5. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome.
    Am J Gastroenterol. 2003 Sep;98(9):2064-71 PMID: 14499789
  6. Diagnosis and interpretation of steatosis and steatohepatitis.
    Semin Diagn Pathol. 1998 Nov;15(4):246-58 PMID: 9845426
  7. Steatosis in donor and transplant liver biopsies.
    Hum Pathol. 2000 Oct;31(10):1209-13 PMID: 11070113
  8. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease.
    Scand J Gastroenterol. 2009;44(3):366-74 PMID: 19016382
  9. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
    Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112 PMID: 16447287
  10. Histological assessment of non-alcoholic fatty liver disease.
    Histopathology. 2006 Nov;49(5):450-65 PMID: 17064291
  11. Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis.
    Hepatogastroenterology. 2001 Jan-Feb;48(37):87-90 PMID: 11269008
  12. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction.
    Gastroenterology. 2007 Jul;133(1):80-90 PMID: 17631134
  13. De novo nonalcoholic fatty liver disease after liver transplantation.
    Liver Transpl. 2007 Jun;13(6):844-7 PMID: 17029282
  14. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.
    Mayo Clin Proc. 1980 Jul;55(7):434-8 PMID: 7382552
  15. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.
    Clin Gastroenterol Hepatol. 2009 Nov;7(11):1224-9, 1229.e1-2 PMID: 19559819
  16. Apoptosis in alcoholic and nonalcoholic steatohepatitis.
    Front Biosci. 2005 Sep 01;10:3093-9 PMID: 15970563
  17. Mitochondria in nonalcoholic fatty liver disease.
    Clin Liver Dis. 2004 Aug;8(3):595-617, x PMID: 15331066
  18. Recurrence of nonalcoholic steatohepatitis following liver transplantation.
    Transplantation. 1996 Dec 27;62(12):1802-5 PMID: 8990367
  19. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease.
    Hepatology. 2008 Jun;47(6):1947-54 PMID: 18454505
  20. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis.
    Liver Transpl. 2001 Apr;7(4):363-73 PMID: 11303298
  21. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease.
    J Hepatol. 2009 Apr;50(4):797-804 PMID: 19231016
  22. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease.
    Clin Gastroenterol Hepatol. 2009 Apr;7(4):481-6 PMID: 19162235
  23. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.
    Gastroenterology. 2001 Apr;120(5):1183-92 PMID: 11266382
  24. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease.
    Liver Transpl. 2001 Sep;7(9):797-801 PMID: 11552214
  25. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.
    Hepatology. 2009 Mar;49(3):851-9 PMID: 19115377
  26. Liver transplantation for cryptogenic cirrhosis.
    Liver Transpl Surg. 1997 Jul;3(4):359-64 PMID: 9346764
  27. Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis.
    Hepatol Res. 2005 Oct;33(2):122-7 PMID: 16890173
  28. Epidemiology and natural history of non-alcoholic steatohepatitis.
    Clin Liver Dis. 2009 Nov;13(4):511-31 PMID: 19818302
  29. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.
    Hepatology. 2009 Oct;50(4):1072-8 PMID: 19585618
  30. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient.
    Liver Transpl Surg. 1997 Mar;3(2):174-6 PMID: 9346732
  31. Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
    Hepatology. 2005 Jun;41(6):1313-21 PMID: 15915461
  32. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.
    Hepatology. 2008 Sep;48(3):792-8 PMID: 18752331
  33. Fatty liver hepatitis and cirrhosis in obese patients.
    Am J Med. 1979 Nov;67(5):811-6 PMID: 507094
  34. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease.
    Mod Pathol. 2003 Jan;16(1):49-56 PMID: 12527713
  35. Histopathology of pediatric nonalcoholic fatty liver disease.
    Hepatology. 2005 Sep;42(3):641-9 PMID: 16116629
  36. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease.
    Liver Transpl. 2001 Jul;7(7):608-14 PMID: 11460228
  37. Sponge artifact in biopsy specimens.
    Arch Pathol Lab Med. 1990 Dec;114(12):1285-7 PMID: 2252429
  38. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates.
    Dig Dis Sci. 2003 Nov;48(11):2173-81 PMID: 14705824
  39. Clinical features and natural history of nonalcoholic steatosis syndromes.
    Semin Liver Dis. 2001;21(1):17-26 PMID: 11296693
  40. Non-alcoholic steatohepatitis in children.
    Clin Liver Dis. 2007 Feb;11(1):155-72, x PMID: 17544977
  41. Advances in pediatric nonalcoholic fatty liver disease.
    Hepatology. 2009 Oct;50(4):1282-93 PMID: 19637286
  42. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease.
    Hepatology. 2005 Feb;41(2):372-9 PMID: 15723436
  43. The incapacity of the surgeon to identify NASH in bariatric surgery makes biopsy mandatory.
    Obes Surg. 2009 Dec;19(12):1678-84 PMID: 19789933
  44. Fibrosis heterogeneity in nonalcoholic steatohepatitis and hepatitis C virus needle core biopsy specimens.
    Am J Clin Pathol. 2005 Mar;123(3):382-7 PMID: 15716234
  45. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients.
    Dig Dis Sci. 1996 Jan;41(1):172-9 PMID: 8565753
  46. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis.
    Semin Diagn Pathol. 2005 Nov;22(4):330-8 PMID: 16939061
  47. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.
    Diabetes. 2001 Aug;50(8):1844-50 PMID: 11473047
  48. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver.
    Hepatology. 2004 Jan;39(1):179-87 PMID: 14752836
  49. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis.
    J Hepatol. 2008 May;48(5):821-8 PMID: 18329127
  50. Obese children with steatohepatitis can develop cirrhosis in childhood.
    Am J Gastroenterol. 2002 Sep;97(9):2460-2 PMID: 12358273
  51. [The fatty liver and its pathogenetic relation to liver cirrhosis].
    Virchows Arch Pathol Anat Physiol Klin Med. 1962;335:180-210 PMID: 13920484
  52. Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population.
    Am J Gastroenterol. 2009 Sep;104(9):2189-95 PMID: 19550408
  53. Race, insulin resistance and hepatic steatosis in chronic hepatitis C.
    Hepatology. 2007 Jan;45(1):80-7 PMID: 17187406
  54. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease.
    Gastroenterology. 2009 Oct;137(4):1478-1488.e8 PMID: 19577569
  55. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
    Hepatology. 2003 Oct;38(4):1008-17 PMID: 14512888
  56. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation.
    Liver Transpl Surg. 1997 Mar;3(2):177-8 PMID: 9346733
  57. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis.
    Gastroenterology. 2008 Feb;134(2):416-23 PMID: 18164296
  58. Mallory bodies revisited.
    J Hepatol. 2000 Apr;32(4):689-702 PMID: 10782920
  59. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice.
    Hepatology. 2006 Aug;44(2):458-65 PMID: 16871574
  60. Non-alcoholic steatohepatitis and cancer.
    Clin Liver Dis. 2007 Feb;11(1):191-207, x-xi PMID: 17544979
  61. Five patients with nonalcoholic diabetic cirrhosis.
    Acta Hepatogastroenterol (Stuttg). 1979 Apr;26(2):90-7 PMID: 463492
  62. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss.
    Hepatology. 2004 Jun;39(6):1647-54 PMID: 15185306
  63. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.
    Am J Gastroenterol. 2005 May;100(5):1072-81 PMID: 15842581
  64. Recurrence of insulin resistant metabolic syndrome following liver transplantation.
    Eur J Gastroenterol Hepatol. 2003 Jan;15(1):99-102 PMID: 12544703
  65. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease.
    Liver. 2001 Aug;21(4):266-71 PMID: 11454190
  66. Recurrence of nonalcoholic steatohepatitis after liver transplantation.
    Liver Transpl Surg. 1997 Mar;3(2):185-6 PMID: 9346736
  67. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers.
    Hepatology. 2008 Feb;47(2):455-60 PMID: 18038452
  68. Histological study on comparison between NASH and ALD.
    Hepatol Res. 2005 Oct;33(2):110-5 PMID: 16219486
  69. Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass.
    Clin Gastroenterol Hepatol. 2007 Nov;5(11):1329-32 PMID: 17702661
  70. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
    Gastroenterology. 1999 Jun;116(6):1413-9 PMID: 10348825
  71. Nonalcoholic fatty liver disease in children: a single center experience.
    Clin Gastroenterol Hepatol. 2008 Jul;6(7):799-802 PMID: 18486560
  72. The evolution of severe steatosis after bariatric surgery is related to insulin resistance.
    Gastroenterology. 2006 May;130(6):1617-24 PMID: 16697725
  73. Methods for assessing intrahepatic fat content and steatosis.
    Curr Opin Clin Nutr Metab Care. 2009 Sep;12(5):474-81 PMID: 19550313
  74. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.
    J Gastroenterol. 2009;44 Suppl 19:89-95 PMID: 19148800
  75. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis.
    Gastroenterology. 2008 Dec;135(6):1961-1971.e2 PMID: 19013463
  76. Does liver appearance predict histopathologic findings: prospective analysis of routine liver biopsies during bariatric surgery.
    Surg Obes Relat Dis. 2009 May-Jun;5(3):323-8 PMID: 19356994
  77. Outcomes of liver transplantation for cryptogenic cirrhosis: a single-center study of 71 patients.
    Transplant Proc. 2003 Dec;35(8):2977-80 PMID: 14697954
  78. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
    Hepatology. 2009 Jan;49(1):306-17 PMID: 19065650
  79. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network.
    Hepatology. 2009 Mar;49(3):809-20 PMID: 19142989
  80. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens.
    Hum Pathol. 2004 Sep;35(9):1070-82 PMID: 15343508
  81. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.
    Hepatology. 2004 Jan;39(1):188-96 PMID: 14752837
  82. Non-alcoholic steatohepatitis in children and adolescents.
    Med J Aust. 2000 Nov 6;173(9):476-9 PMID: 11149304
  83. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study.
    Hepatology. 2007 Aug;46(2):380-7 PMID: 17659580
  84. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver.
    Hum Pathol. 2000 Jul;31(7):822-8 PMID: 10923919
  85. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients.
    Diabetes Care. 2007 May;30(5):1212-8 PMID: 17277038
  86. Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease.
    Clin Gastroenterol Hepatol. 2005 Apr;3(4):384-9 PMID: 15822044
  87. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.
    Am J Gastroenterol. 1999 Sep;94(9):2467-74 PMID: 10484010
  88. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems.
    Eur J Gastroenterol Hepatol. 2010 Jun;22(6):643-50 PMID: 19478676
  89. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future.
    Hepatology. 2007 Aug;46(2):582-9 PMID: 17661414
  90. Fatty liver in liver transplantation and surgery.
    Semin Liver Dis. 2001;21(1):105-13 PMID: 11296690
  91. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis.
    J Hepatol. 2009 Aug;51(2):371-9 PMID: 19501928
  92. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.
    Hepatology. 2003 May;37(5):1202-19 PMID: 12717402
  93. The natural history of nonalcoholic fatty liver disease: a population-based cohort study.
    Gastroenterology. 2005 Jul;129(1):113-21 PMID: 16012941
  94. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.
    Gastroenterology. 2001 Jul;121(1):91-100 PMID: 11438497
  95. Alcoholic liver disease.
    Semin Diagn Pathol. 2006 Aug-Nov;23(3-4):149-60 PMID: 17355088
  96. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies.
    Hepatology. 2004 Oct;40(4):820-6 PMID: 15382171
  97. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases.
    Transplantation. 2000 Jul 27;70(2):292-7 PMID: 10933151
  98. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.
    Hepatology. 2003 Jun;37(6):1286-92 PMID: 12774006
  99. Nonalcoholic steatohepatitis.
    Semin Liver Dis. 2004 Feb;24(1):3-20 PMID: 15085483
  100. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD.
    Am J Gastroenterol. 2006 Oct;101(10):2247-53 PMID: 17032189
  101. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group.
    Gastroenterology. 1993 Feb;104(2):595-603 PMID: 8425703
  102. The use of protein tyrosine phosphatase 1B and insulin receptor immunostains to differentiate nonalcoholic from alcoholic steatohepatitis in liver biopsy specimens.
    Am J Clin Pathol. 2005 Apr;123(4):503-9 PMID: 15743753
  103. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease.
    Gastroenterology. 2010 Mar;138(3):905-12 PMID: 19931264
  104. Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning.
    J Atheroscler Thromb. 2009;16(6):893-901 PMID: 20032580
  105. Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research.
    J Pediatr Gastroenterol Nutr. 2006 Oct;43(4):413-27 PMID: 17033514
  106. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis.
    Liver Transpl. 2009 Dec;15(12):1843-51 PMID: 19938117
  107. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.
    Gastroenterology. 2002 Jul;123(1):134-40 PMID: 12105842
  108. Long-term follow-up of patients with NAFLD and elevated liver enzymes.
    Hepatology. 2006 Oct;44(4):865-73 PMID: 17006923
  109. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease.
    Liver Int. 2006 Nov;26(9):1021-8 PMID: 17032401
  110. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.
    Hepatology. 2010 Feb;51(2):445-53 PMID: 19877169
  111. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.
    Hepatology. 2006 Jul;44(1):27-33 PMID: 16799979
  112. Sampling variability of liver biopsy in nonalcoholic fatty liver disease.
    Gastroenterology. 2005 Jun;128(7):1898-906 PMID: 15940625
  113. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years.
    Gut. 2009 Nov;58(11):1538-44 PMID: 19625277
  114. Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease.
    Liver Int. 2005 Apr;25(2):294-304 PMID: 15780053
  115. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease.
    Hepatology. 2006 Oct;44(4):874-80 PMID: 17006934
  116. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis.
    Hepatology. 2007 Aug;46(2):424-9 PMID: 17559148
  117. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.
    Hepatology. 2007 Apr;45(4):846-54 PMID: 17393509
  118. Sources of variability in histological scoring of chronic viral hepatitis.
    Hepatology. 2005 Feb;41(2):257-64 PMID: 15660389
  119. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.
    J Hepatol. 2008 Oct;49(4):608-12 PMID: 18682312
  120. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease.
    Am J Gastroenterol. 2004 Jul;99(7):1316-20 PMID: 15233671
  121. From Mallory to Mallory-Denk bodies: what, how and why?
    Exp Cell Res. 2007 Jun 10;313(10):2033-49 PMID: 17531973
  122. Utility of a new model to diagnose an alcohol basis for steatohepatitis.
    Gastroenterology. 2006 Oct;131(4):1057-63 PMID: 17030176
  123. Excess weight risk factor for alcoholic liver disease.
    Hepatology. 1997 Jan;25(1):108-11 PMID: 8985274
  124. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?
    Arch Pathol Lab Med. 2008 Nov;132(11):1761-6 PMID: 18976012
  125. The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients.
    Am J Gastroenterol. 2009 Jan;104(1):64-9 PMID: 19098851
  126. Non-alcoholic fatty liver disease: is bariatric surgery the answer?
    Clin Liver Dis. 2009 Nov;13(4):689-710 PMID: 19818313
  127. Liver fibrosis in overweight patients.
    Gastroenterology. 2000 Jun;118(6):1117-23 PMID: 10833486
  128. Long-term follow-up of patients with nonalcoholic fatty liver.
    Clin Gastroenterol Hepatol. 2009 Feb;7(2):234-8 PMID: 19049831
  129. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.
    Liver Int. 2006 Mar;26(2):151-6 PMID: 16448452
  130. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
    Hepatology. 2004 Mar;39(3):770-8 PMID: 14999696
  131. Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology.
    J Hepatol. 2001 Aug;35(2):195-9 PMID: 11580141
  132. The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis.
    Hepatology. 2004 May;39(5):1423-9 PMID: 15122772
  133. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations.
    Mod Pathol. 1998 Jun;11(6):560-5 PMID: 9647594
  134. Transient elastography in nonalcoholic fatty liver disease: making sense of echoes.
    Hepatology. 2010 Feb;51(2):370-2 PMID: 20054871
  135. Who gets alcoholic liver disease: nature or nurture?
    J R Coll Physicians Lond. 2000 Nov-Dec;34(6):557-62 PMID: 11191974
  136. Nonalcoholic steatohepatitis in children.
    J Pediatr Gastroenterol Nutr. 2000 Jan;30(1):48-53 PMID: 10630439
  137. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease.
    Hepatology. 2010 Feb;51(2):454-62 PMID: 20101745
  138. Morphology of alcoholic liver disease.
    Clin Liver Dis. 2005 Feb;9(1):37-53 PMID: 15763228
  139. Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents.
    Semin Liver Dis. 2007 Aug;27(3):312-8 PMID: 17682977
  140. Do you see what I see? The role of quality histopathology in scientific study.
    Hepatology. 2008 Mar;47(3):771-4 PMID: 18302289
  141. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis.
    J Clin Gastroenterol. 2004 Oct;38(9):801-4 PMID: 15365409
  142. Relation of steatosis to cirrhosis.
    Clin Gastroenterol. 1975 May;4(2):273-80 PMID: 1126047
  143. Silent non-alcoholic fatty liver disease-a clinical-histological study.
    J Hepatol. 2004 Nov;41(5):751-7 PMID: 15519647
Article Info
Journal
World journal of gastroenterology
Abbr.
World J Gastroenterol
ISSN
2219-2840
DOI
10.3748/wjg.v16.i42.5286
Email
[email protected]
Published
2010-11-14
Pages
5286-96
Language
English
Region
United States
NLM ID
100883448
PMCID
PMC2980677
Subset
IM
Grants
NCI NIH HHS · P50 CA095817 · United States
External Links
PubMed source DOI: 10.3748/wjg.v16.i42.5286 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2